# BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect

> **NCT03638180** · PHASE1 · COMPLETED · sponsor: **Bellus Health Inc. - a GSK company** · enrollment: 90 (actual)

## Conditions studied

- Cough

## Interventions

- **DRUG:** BLU-5937
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03638180
- **Lead sponsor:** Bellus Health Inc. - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-09
- **Primary completion:** 2018-10-25
- **Final completion:** 2018-10-25
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2018-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03638180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03638180, "BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03638180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*